Share This Article:

Bisphosphonate-related osteonecrosis of the jaws: A report on 30 cases

Abstract Full-Text HTML Download Download as PDF (Size:230KB) PP. 247-254
DOI: 10.4236/ojst.2013.34043    2,819 Downloads   4,238 Views  

ABSTRACT

Aim: To report a series of thirty cases of bisphosphonate-related osteonecrosis of the jaw (BRONJ). Material and Methods: For 30 patients with BRONJ, gender, age, underlying diagnosis, type of bisphosphonate (BP), administration route and duration, location and stage of osteonecrosis, symptoms and oral health status, radiological findings of the jaws, treatment and outcome, were recorded. Results: Underlying diagnoses in the series (12 male; 18 female; mean age 70.50 ± 9.62) were: 12 multiple myeloma, 7 breast cancer, 3 prostate carcinoma, 1 kidney/lung/ bladder/mediastinal cancer, 1 chronic lymphocytic leukemia, 1 osteoporosis, 1 palatal osteosarcoma + osteoporosis, 1 non-Hodgkin’s lymphoma. Forty-seven osteonecrotic lesions were detected; 30 localized in the mandible,17 inthe maxilla; trigger events were tooth extraction in 31 cases (66%), periodontal disease in 4 (8.50%), incongruous dentures in 3 (6.40%), perimplantitis in 1 (2.10%), unknown in 8 (17%). Twenty-nine patients had received treatment using amino bisphosphonates (25 zoledronate, 2 pamidronate, 2 alendronate) and 1 clodronate; the administration route was intravenous in 27 patients, oral in 2 and intramuscular in 1. Mean number of doses to bone exposure for patients was 34.11 for zoledronate, 50.50 for pamidronate, 146 for alendronate, and 500 for clodronate. Among statistical data the only significant finding was that panoramic dental radiography gave no concrete support for diagnosis of ONJ lesions (p ≤ 0.04). Conclusions: Our case series reflects literature data. We emphasize the insufficient role of panoramic radiography to study osteonecrotic lesions and the role of poor oral hygiene.

Conflicts of Interest

The authors declare no conflicts of interest.

Cite this paper

Migliario, M. , Melle, A. , Fusco, V. and Rimondini, L. (2013) Bisphosphonate-related osteonecrosis of the jaws: A report on 30 cases. Open Journal of Stomatology, 3, 247-254. doi: 10.4236/ojst.2013.34043.

References

[1] Rodan, G.A. and Fleisch, H.A. (1996) Bisphosphonates: Mechanism of action. Journal of Clinical Investigation, 97, 2692-2696. doi:10.1172/JCI118722
[2] Russel, R.G. and Rogers, M.J. (1999) Bisphosphonates: From the laboratory to the clinic and back again. Bone, 25, 97-106. doi:10.1016/S8756-3282(99)00116-7
[3] Corrado, A. and Cantatore, F.P. (2005) The bisphosphonates: Chemical characteristics, skeletal biological effects and extra-skeletal effects. Reumatismo, 57, 142-153.
[4] Berenson, J.R., Hillner, B.E., Kyle, R.A., Anderson, K. Lipton, A. Yee, G.C. and Biermann J.S. (2002) American Society of Clinical Oncology clinical practice guidelines: The role of bisphosphonates in multiple myeloma. Bisphosphonates Expert Panel. Journal of Clinical Oncology, 20, 3719-3736. doi:10.1200/JCO.2002.06.037
[5] Wu, S., Dahut, W.L. and Gulley, J.L. (2007) The use of bisphosphonates in cancer patients. Acta Oncologica, 46, 581-591. doi:10.1080/02841860701233435
[6] Delmas, P.D. and Meunier, P.J. (1997) The management of Paget’s disease of bone. New England Journal of Medicine, 336, 558-566. doi:10.1056/NEJM199702203360807
[7] Watts, N.B. (2003) Bisphosphonate treatment of osteoporosis. Clinics in Geriatrics Medicine, 19, 395-414. doi:10.1016/S0749-0690(02)00069-1
[8] Hillner, B.E., Ingle, J.N., Chlebowski, R.T., Gralow, J. Yee, G.C., Janjan, N.A., Cauley, J.A., Blumenstein, B.A., Albain, K.S., Lipton, A. and Brown, S. (2003) American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. Journal of Clinical Oncology, 21, 4042- 4057. doi:10.1200/JCO.2003.08.017
[9] Aapro, M., Abrahamsson, P.A., Body, J.J., Coleman, R.E., Colomer, R., Costa, L., Crinò, L., Dirix, L., Gnant, M., Gralow, J., Hadji, P., Hortobagyi, G.N., Jonat, W., Lipton, A., Monnier, A., Paterson, A.H., Rizzoli, R., Saad, F. and Thürlimann, B. (2008) Guidance on the use of bisphos- phonates in solid tumours: recommendations of an international expert panel. Annals of Oncology, 19, 420-432. doi:10.1093/annonc/mdm442
[10] Landesberg, R., Eisig, S, Fennoy, I. and Siris, E. (2009) Alternative indications for bisphosphonate therapy. Journal of Oral and Maxillofacial Surgery, 67, 27-34. doi:10.1016/j.joms.2008.12.006
[11] Mehrotra, B. (2009) Bisphosphonates—Role in cancer therapies. Journal of Oral and Maxillofacial Surgery, 67, 19-26. doi:10.1016/j.joms.2009.01.012
[12] Marx, R.E. (2003) Pamidronate (Aredia) and zoledronate (Zometa) induced avascolar necrosis of the jaws: A growing epidemic. Journal of Oral and Maxillofacial Surgery, 61, 1115-1117. doi:10.1016/S0278-2391(03)00720-1
[13] Migliorati, C.A. (2003) Bisphosphonates and oral cavity avascular bone necrosis. Journal of Clinical Oncology, 21, 4253-4254. doi:10.1200/JCO.2003.99.132
[14] American Association of Oral and Maxillofacial Surgeons (2006) Position paper on bisphosphonate-related osteonecrosis of the Jaws. 1-17.
[15] Ruggiero, S.L., Dodson, T.B., Assael, L.A., Landesberg, R., Marx, R.E. and Mehrotra, B. (2009) American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws 2009 update. Journal of Oral and Maxillofacial Surgery, 67, 2-12. doi:10.1016/j.joms.2009.01.009
[16] Ruggiero, S.L., Mehrotra, B., Rosenberg, T.J. and Eng- roff, S.L. (2004) Osteonecrosis of the jaws associated with the use of bisphosphonates: A review of 63 cases. Journal of Oral and Maxillofacial Surgery, 62, 527-534. doi:10.1016/j.joms.2004.02.004
[17] Bamias, A., Kastritis, E., Bamias, C., Melakopoulos, I., Bozas, G., Koutsoukou, V., Gika, D., Anagnostopoulos, A., Papadimitriou, C., Terpos, E. and Dimopoulos, M.A. (2005) Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: Incidence and risk factors. Journal of Clinical Oncology, 23, 8580-8587. doi:10.1200/JCO.2005.02.8670
[18] Durie, B.G., Katz, M. and Crowley, J. (2005) Osteonecrosis of the jaw and bisphosphonates. New England Journal of Medicine, 353, 99-102. doi:10.1056/NEJM200507073530120
[19] Migliorati, C.A., Schubert, M.M., Peterson, D.E. and Seneda, L.M. (2005) Bisphosphonate-associated osteone- crosis of mandibular and maxillary bone: An emerging oral complication of supportive cancer therapy. Cancer, 104, 83-93. doi:10.1002/cncr.21130
[20] Dimopoulos, M.A., Kastritis, E., Anagnostopoulos, A., Melakopoulos, I., Gika, D., Moulopoulos, L.A., Bamia, C., Terpos, E., Tsionos, K. and Bamias, A. (2006) Os- teonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: Evidence of increased risk after treatment with zoledronic acid. Haematologica, 91, 968-971.
[21] Diel, I.J., Bergner, R. and Grotz, K.A. (2007) Adverse effects of bisphosphonates: Current issues. Journal of Supportive Oncology, 5, 475-482.
[22] Wang, E.P., Kaban, L.B., Strewler, G.J., Raje, N. and Troulis, M.J. (2007) Incidence of osteonecrosis of the jaw in patients with multiple myeloma and breast or prostate cancer on intravenous bisphosphonate therapy. Journal of Oral and Maxillofacial Surgery, 65, 1328-1331. doi:10.1016/j.joms.2007.03.006
[23] Wessel, J.H., Dodson, T.B. and Zavras, A. (2008) Zoledronate, smoking, and obesity are strong risk factor for osteonecrosis of the jaw: A case-control study. Journal of Oral and Maxillofacial Surgery, 66, 625-631. doi:10.1016/j.joms.2007.11.032
[24] Dodson, T.B. (2009) Intravenous bisphosphonates thera- py and bisphosphonate-related osteonecrosis of the jaws. Journal of Oral and Maxillofacial Surgery, 67, 44-52. doi:10.1016/j.joms.2008.12.004
[25] Hoff, A.O., Toth, B., Hu, M., Hortobagyi, G.N. and Gagel, R.F. (2011) Epidemiology and risk factors for osteonecrosis of the jaw in cancer patients. Annals of New York Academy of Sciences, 1218, 47-54. doi:10.1111/j.1749-6632.2010.05771.x
[26] Campisi, G., Lo Russo, L., Agrillo, A., Vescovi, P., Fusco, V. and Bedogni, A. (2011) A BRONJ expert panel recommendation of the Italian Society for Maxillofacial Surgery (SICMF) and Oral Pathology and Medicine (SIPMO) on bisphosphonate-related osteonecrosis of the jaws: Risk assessment, preventive strategies and dental management. Italian Journal of Maxillofacial Surgery, 22, 103-124.
[27] Khosla, S., Burr, D., Cauley, J., Dempster, D.W., Ebeling, P.R., Felsenberg, D., Gagel, R.F., Gilsanz, V., Guise, T., Koka, S., McCauley, L.K., McGowan, J., McKee, M.D., Mohla, S., Pendrys, D.G., Raisz, L.G., Ruggiero, S.L., Shafer, D.M., Shum, L., Silverman, S.L., Van Poznak, C.H., Watts, N., Woo, S.B. and Shane, E. (2007) Bisphosphonate-associated osteonecrosis of the jaw: Report of a task force of the American Society for Bone and Mineral Research. Journal of Bone and Mineral Research, 22, 1479-1491. doi:10.1359/jbmr.0707onj
[28] Yarom, N., Yahalom, R., Shoshani, Y., Hamed, W., Regev, E. and Elad, S. (2007) Osteonecrosis of the jaw induced by orally administered bisphosphonates: Incidence, clinical features, predisposing factors and treatment outcome. Osteoporosis International, 18, 1363-1370. doi:10.1007/s00198-007-0384-2
[29] Crépin, S., Laroche, M.L., Sarry, B., and Merle, L. (2010) Osteonecrosis of the jaw induced by clodronate, an alkylbiphosphonate: Case report and literature review. European Journal of Clinical Pharmacology, 66, 547-554. doi:10.1007/s00228-010-0822-5
[30] Lo J.C., O’Ryan, F.S., Gordon, N.P., Yang, J., Hui, R.L., Martin, D., Hutchinson, M., Lathon, P.V., Sanchez, G., Silver, P., Chandra, M., McCloskey, C.A., Staffa, J.A., Willy, M., Selby, J.V. and Go, A.S. (2010) Prevalence of osteonecrosis of the jaw in patients with oral bisphosphonate exposure. Journal of Oral and Maxillofacial Surgery, 68, 243-253. doi:10.1016/j.joms.2009.03.050
[31] Otto, S., Abu-Id, M.H., Fedele, S., Warnke, P.H., Becker, S.T., Kolk, A., Mücke, T., Mast, G., K?hnke, R., Volk- mer, E., Haasters, F., Lieger, O., Iizuka, T., Porter, S., Campisi, G., Colella, G., Ploder, O., Neff, A., Wiltfang, J., Ehrenfeld, M., Kreusch, T., Wolff, K.D., Stürzenbaum, S.R., Schieker, M. and Pautke, C. (2011) Osteoporosis and bisphosphonates-related osteonecrosis of the jaw: Not just a sporadic coincidence—A multicentre study. Journal of Cranio-Maxillo-Facial Surgery, 39, 272-277. doi:10.1016/j.jcms.2010.05.009
[32] Malden, N. and Lopes, V. (2012) An epidemiological study of alendronate-related osteonecrosis of the jaws. A case series from the south-east of Scotland with attention given to case definition and prevalence. Journal of Bone and Mineral Metabolism, 30, 171-182. doi:10.1007/s00774-011-0299-z
[33] Loe, H. and Silness, J. (1963) Periodontal disease in pregnancy. I. Prevalence and severity. Acta Odontologica Scandinavica, 21, 533-551. doi:10.3109/00016356309011240
[34] Silness, J. and Loe, H. (1964) Periodontal disease in pregnancy. II. Correlation between oral hygiene and pe- riodontal correlation. Acta Odontologica Scandinavica, 22, 121-135. doi:10.3109/00016356408993968
[35] Chiandussi, S., Biasotto, M., Dore, F., Cavalli, F., Cova, M.A. and Di Lenarda, R. (2006) Clinical and diagnostic imaging of bisphosphonate-induced osteonecrosis of the jaws. Dento Maxillo Facial Radiology, 35, 236-243. doi:10.1259/dmfr/27458726
[36] Arce, K., Assael, L.A., Weissman, J.L. and Markiewicz, M.R. (2009) Imaging findings in bisphosphonate-related osteonecrosis of the jaws. Journal of Oral and Maxillofacial Surgery, 67, 75-84. doi:10.1016/j.joms.2008.12.002
[37] Assael, L.A. (2009) Oral bisphosphonates as a cause of bisphosphonate-related osteonecrosis of the jaws: Clinical findings, assessment of risks, and preventive strategies. Journal of Oral and Maxillofacial Surgery, 67, 35-43. doi:10.1016/j.joms.2009.01.003
[38] Stockmann, P., Hinkmann, F.M., Lell, M.M., Fenner, M., Vairaktaris, E., Neukam, F.W. and Nkenke, E. (2010) Panoramic radiograph, computed tomography or magnetic resonance imaging. Which imaging technique should be preferred in bisphosphonate-associated osteonecrosis of the jaw? A prospective clinical study. Clinical Oral Investigations, 14, 311-317. doi:10.1007/s00784-009-0293-1
[39] Ruggiero, S.L., Fantasia, J. and Carlson, E. (2006) Bisphosphonate-related osteonecrosis of the jaw: Background and guidelines for diagnosis, staging and management. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology and Endodontics, 102, 433-441. doi:10.1016/j.tripleo.2006.06.004
[40] Carlson, E.R. and Basile J.D. (2009) The role of surgical resection in the management of bisphosphonate-related osteonecrosis of the jaws. Journal of Oral and Maxillofacial Surgery, 67, 85-95. doi:10.1016/j.joms.2009.01.006
[41] Marx, R.E. (2009) Reconstruction of defects caused by bisphosphonate-induced osteonecrosis of the jaws. Journal of Oral and Maxillofacial Surgery, 67, 107-119. doi:10.1016/j.joms.2008.12.007
[42] Agrillo, A., Filiaci, F., Ramieri, V., Riccardi, E., Quarato, D., Rinna, C., Gennaro, P., Cascino, F., Mitro, V. and Ungari, C. (2012) Bisphosphonate-related osteonecrosis of the jaw (BRONJ): 5 years experience in the treatment of 131 cases with ozone therapy. European Review for Medical and Pharmacological Sciences, 16, 1741-1747.
[43] Woo, S.B., Hellstein, J.W. and Kalmar, J.R. (2006) Nar- rative review: Bisphosphonates and osteonecrosis of the jaws. Annals of Internal Medicine, 144, 753-761. doi:10.7326/0003-4819-144-10-200605160-00009
[44] Allen, M.R. and Burr, D.B. (2009) The pathogenesis of bisphosphonate-related osteonecrosis of the jaw: So many hypotheses, so few data. Journal of Oral Maxillofacial Surgery, 67, 61-70. doi:10.1016/j.joms.2009.01.007
[45] Thumbigere-Math, V., Sabino, M.C., Gopalakrishnan, R., Huckabay, S., Dudek, A.Z., Basu, S., Hughes, P.J., Michalowicz, B.S., Leach, J.W., Swenson, K.K., Swift, J.Q., Adkinson, C. and Basi, D.L. (2009) Bisphosphonate-related osteonecrosis of the jaw: Clinical features, risk factors, management, and treatment outcomes of 26 patients. Journal of Oral and Maxillofacial Surgery, 67, 1904-1913. doi:10.1016/j.joms.2009.04.051
[46] Vahtsevanos, K., Kyrgidis, A., Verrou, E., Katodritou, E., Triaridis, S., Andreadis, C.G., Boukovinas, I., Koloutsos, G.E., Teleioudis, Z., Kitikidou, K., Paraskevopoulos, P., Zervas, K. and Antoniades, K. (2009) Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw. Journal of Clinical Oncology, 27, 5356-5362. doi:10.1200/JCO.2009.21.9584
[47] Barasch, A., Cunha-Cruz, J., Curro, F.A., Hujoel, P., Sung, A.H., Vena, D., Voinea-Griffin, A.E. (CONDOR Collaborative Group) Beadnell, S., Craig, R.G., DeRouen, T., Desaranayake, A., Gilbert, A., Gilbert, G.H., Gold- berg, K., Hauley, R., Hashimoto, M., Holmes, J., Latzke, B., Leroux, B., Lindblad, A., Richman, J., Safford, M., Ship, J., Thompson, V.P., Williams, O.D. and Yin, W. (2011) Risk factors for osteonecrosis of the jaws: A case-control study from the CONDOR dental PBRN. Journal of Dental Research, 90, 439-444. doi:10.1177/0022034510397196
[48] Katz, J., Gong, Y., Salmasinia, D., Hou, W., Burkley, B., Ferreira, P., Casanova, O., Langaee, T.Y. and Moreb, J.S. (2011) Genetic polymorphisms and other risk factors associated with bisphosphonate induced osteonecrosis of the jaw. International Journal of Oral and Maxillofacial Surgery, 40, 605-611. doi:10.1016/j.ijom.2011.02.002
[49] Ruggiero, S.L. (2009) Bisphosphonate-related osteonecrosis of the jaw (BRONJ): Initial discovery and subsequent development. Journal of Oral and Maxillofacial Surgery, 67, 13-18. doi:10.1016/j.joms.2008.10.005
[50] Colella, G., Campisi, G. and Fusco, V. (2009) American Association of Oral and Maxillofacial Surgeons position paper: Bisphosphonate-related osteonecrosis of the jaws- 2009 update: The need to refine the BRONJ definition. Journal of Oral and Maxillofacial Surgery, 67, 2698- 2699. doi:10.1016/j.joms.2009.07.097
[51] Bedogni, A., Fusco, V., Agrillo, A. and Campisi, G. (2012) Learning from experience. Proposal of a refined definition and staging system for bisphosphonate-related osteonecrosis of the jaw (BRONJ). Oral Diseases, 18, 621-623. doi:10.1111/j.1601-0825.2012.01903.x
[52] Campisi, G., Di Fede, O., Musciotto, A., Lo Casto, A., Lo Muzio, L., Fulfaro, F., Badalamenti, G., Russo, A. and Gebbia, N. (2007) Bisphosphonate-related osteonecrosis of the jaw (BRONJ): Run dental management design and issues in diagnosis. Annals of Oncology, 18, 168-172. doi:10.1093/annonc/mdm250
[53] Ripamonti, C.I., Maniezzo, M., Campa, T., Fagnoni, E., Brunelli, C., Saibene, G., Bareggi, C., Ascani, L. and Cislaghi, E. (2009) Decrease occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan. Annals of Oncology, 20, 137-145. doi:10.1093/annonc/mdn526
[54] Vandone, A.M., Donadio, M., Mozzati M., Ardine, M., Polimeni, M.A., Beatrice, S., Ciuffreda, L. and Scoletta, M. (2011) Impact of dental care in the prevention of bisphosphonate-associated osteonecrosis of the jaw: A single-center clinical experience. Annals of Oncology, 23, 193-200. doi:10.1093/annonc/mdr039

  
comments powered by Disqus

Copyright © 2018 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.